| Literature DB >> 25436884 |
Fabrizio Bruschi1, Barbara Pinto2.
Abstract
Matrix metalloproteinases (MMPs) represent a large family of over twenty different secreted or membrane-bound endopeptidases, involved in many physiological (embryogenesis, precursor or stem cell mobilization, tissue remodeling during wound healing, etc.), as well as pathological (inflammation, tumor progression and metastasis in cancer, vascular pathology, etc.) conditions. For a long time, MMPs were considered only for the ability to degrade extracellular matrix (ECM) molecules (e.g., collagen, laminin, fibronectin) and to release hidden epitopes from the ECM. In the last few years, it has been fully elucidated that these molecules have many other functions, mainly related to the immune response, in consideration of their effects on cytokines, hormones and chemokines. Among others, MMP-2 and MMP-9 are endopeptidases of the MMP family produced by neutrophils, macrophages and monocytes. When infection is associated with leukocyte influx into specific organs, immunopathology and collateral tissue damage may occur. In this review, the involvement of MMPs and, in particular, of gelatinases in both protozoan and helminth infections will be described. In cerebral malaria, for example, MMPs play a role in the pathogenesis of such diseases. Also, trypanosomosis and toxoplasmosis will be considered for protozoan infections, as well as neurocysticercosis and angiostrongyloidosis, as regards helminthiases. All these situations have in common the proteolytic action on the blood brain barrier, mediated by MMPs.Entities:
Year: 2013 PMID: 25436884 PMCID: PMC4235708 DOI: 10.3390/pathogens2010105
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Matrix metalloproteinase (MMP) family subgroups.
| Common name | MMP | Chromosomal location (human) | M.W. (kDa) | Collagen substrates | Some additional substrates* |
|---|---|---|---|---|---|
|
| |||||
| Collagenase-1 | MMP-1 | 11q22-q23 | 55/45 | I, II,III, VII, VIII, X, | Aggrecan, gelatin |
| Collagenase-2 | MMP-8 | 11q21-q22 | 75/58 | I, II, III, VII, VIII X | Aggrecan, gelatin, fibronectin |
| Collagenase-3 | MP-13 | 11q22.3 | 60/48 | I, II, III, IV, IX, X, XIV | Aggrecan, gelatin, fibronectin |
| Collagenase-4 | MMP-18 | (
| 70/53 | ||
|
| |||||
| Gelatinasi A | MMP-2 | 16q13 | 72/66 | I, II, III, IV, VII, X | Gelatin, fibronectin, fibrillin |
| Gelatinasi B | MMP-9 | 20q11.2-q13.1 | 92/86 | IV, V | Gelatin, elastin, fibrillin |
|
| |||||
| Stromelysin -1 | MMP-3 | 11q23 | 57/45 | II, III, IV,V,IX, X, XI | Gelatin, plasminogen |
| Stromelysin -2 | MMP-10 | 11q22.3-q23 | 57/44 | IV, | Laminin, fibronectin elastin, |
| Stromelysin -3 | MMP-11 | 22q11.2 | 51/44 | IV | Fibronectin, laminin, aggrecan |
|
| |||||
| Matrylisin-1 | MMP-7 | 11q21-q22 | 28/19 | IV | Fibronectin, laminin, gelatin |
| Matrylisin-2 | MMP-26 | 11p-15 | 28/19 | IV | Fibrinogen, fibronectin, gelatin |
| Metalloelastase | MMP-12 | 11q22.2-q22.3 | 54/45 | IV | Elastin, fibronectin, latent TNF |
|
| |||||
| Tm-type I | |||||
| MT1-MMP | MMP-14 | 14q11-q12 | 66/56 | I, II, III | Gelatin, fibronectin, laminin |
| MT2-MMP | MMP-15 | 15q13-q21 | 72/60 | Gelatin, fibronectin, laminin | |
| MT3-MMP | MMP-16 | 8q21 | 64/52 | III | Gelatin, fibronectin, laminin |
| MT5-MMP | MMP-24 | 20q11.2 | -/52 | Gelatin, fibronectin, laminin | |
| GPI-anchored | Fibrinogen, fibrin | ||||
| MT4-MMP | MMP-17 | 12q24.3 | 57/63 | Fibrin, gelatin | |
| MT6-MMP | MMP-25 | 16p13.3 | IV | Fibronectin, gelatin, laminin | |
|
| |||||
| MMP-19 | 12q14 | 54/45 | IV | ||
| Enamelysin | MMP-20 | 11q22.3 | 54/22 | Aggrecan, elastin, fibrillin Gelatin | |
| MMP-21 | ND | 70/53 | Aggrecan | ||
| CA-MMP | MMP-23 | 1p36.3 | Aggrecan | ||
| MMP-27 | 11q24 | Gelatin, casein, fibronectin | |||
| Epylisin | MMP-28 | 17q21.1 | 56/45 | Casein |
ND = not determined. TNF = tumor necrosis factor. *The list of substrates is by no means exhaustive.
Figure 1Domain structure of the mammalian MMP family. The important features of matrix metalloproteinases (MMPs) are illustrated, showing the minimal domain structures. Although MMPs are often subdivided into groups on the basis of differences in domain composition (shown here), there is little consensus in the field about how such subdivisions should be assigned. Domain structure alone does not predict function. One clear division is between MMPs that are secreted and those that are anchored to the cell surface by an intrinsic motif: namely, a transmembrane (TM) domain (MMP14, -15, -16 and -24), a glycosylphosphatidylinositol (GPI) anchor (MMP17 and MMP25) or an amino (N)-terminal signal anchor (SA) (MMP23). Both the TM domains and GPI anchors are attached to the hemopexin-like domain by a short linker. As discussed in the text, the secreted MMPs might still be confined to the cell surface through interactions with specific accessory macromolecules. Because the mechanisms that control activation (that is, conversion of proMMP to active MMP) are key steps in the regulation of proteolysis, another grouping of the MMPs can be made on the basis of intracellular activation by furin proteinases. Nine MMPs, including all of the membrane-anchored enzymes, have a furin-recognition domain. C5, type-V-collagen-like domain; Col, collagenase-like protein; Cs, cytosolic; Cys, cysteine array; Fn, fibronectin repeat; Fr, furin-cleavage site; Pro, pro-domain; SH, thiol group; SP, signal peptide; Zn, zinc. From [35], with permission.
Figure 2Some aspects of pathogenesis of cerebral malaria. In brains of patients who died with cerebral malaria, TGF-beta1 immunoreactivity (brown color) was found in astrocytes that form the blood-brain barrier around cerebral capillaries, characterized by deposition of malarial pigment and sequestration (a). TGF-beta2 (brown color) immunoreactivity was found in macrophages/microglial cells in Dürck´s granulomas and in glioses of ring hemorrhages (b). TGF-beta3 immunoreactivity (brown color) was found in endothelial and smooth muscle cells in capillaries with deposition of malarial pigment and sequestration (c). All slices were counterstained with hematoxylin eosin. Bars = 25 μm. (From [113], with permission.)
Figure 3Example of gelatin zymography for detection of MMP-9 and MMP-2 activities in serum samples of patients with neurocysticercosis (NCC) and healthy controls (HC). Human Pro-MMP-9 (~ 95 kDa) and Pro-MMP-2 (~ 66 kDa) standards were used as positive controls (Calbiochem Co.). Lanes 1–5 in gel A correspond to serial dilution of recombinant pro-MMP-9; lanes 1–5 in gel B correspond to serial dilutions of recombinant MMP-2. For both gel A and gel B, lanes 6–10 are samples of infected individuals (line 6 and line 10 correspond to individuals with asymptomatic neurocysticercosis); lanes 11–14 are control groups of non-infected individuals; in lane 15, a molecular weight marker (MW) (Bio-Rad, U.S.A.) was loaded.
Figure 4Zymography analysis of matrix metalloproteinase (MMP) activities in sera of healthy controls (HC), asymptomatic neurocysticercosis (AN) and symptomatic neurocysticercosis (SN). (a) MMP-2; (b) MMP-9. From [129], with permission.
Summary of MMP and tissue inhibitor metalloproteinase (TIMP) modifications during parasitic infections of the Central Nervous System (CNS).
| Parasitic infection | MODIFICATION OF MMP levels | MOFIFICATION OF TIMP levels | Refs. |
|---|---|---|---|
| Cerebral malaria | MMP-9 levels increased or unchanged | TIMP-2 level decreased | [ |
| MMP-8 level increased [ | TIMP-1 level increased | [ | |
| MMP-1 accumulation in CNS [ | [ | ||
| African trypanosomosis | MMP-2 and MMP-9 levels increased | TIMP-1 and TIMP-2 levels unchanged | [ |
| Cerebral toxoplasmosis | MMP-8 and MMP-10 produced by CD4+ and CD8+ T cells | Expression of TIMP-1 in the CNS | [ |
| Neurocysticercosis | MMP-2 and MMP-9 levels increate in symptomatic patients [ | [ | |
| Angiostrongyloidosis | MMP-9 accumulation in inflammatory cells invading the CNS in experimental infection [ | [ | |
| TIMP-1 level increased in patients | |||
| MMP-2 and MMP-9 levels increased in patient | TIMP-4 level decreased | [ |